IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 3378 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (74 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  


  In this article
    References

 Article Access Statistics
    Viewed3630    
    Printed50    
    Emailed2    
    PDF Downloaded42    
    Comments [Add]    

Recommend this journal

 
LETTER TO EDITOR
Year : 2003  |  Volume : 69  |  Issue : 6  |  Page : 430
 

Response by the authors


Wallace Pharmaceutical Ltd., Mumbai

Correspondence Address:
Wallace Pharmaceutical Ltd., Mumbai



How to cite this article:
Sharma A D, Gupte P D, Sundaram M, Janaki V R, Rege V L, Bilimoria F E, Arora J. Response by the authors. Indian J Dermatol Venereol Leprol 2003;69:430


How to cite this URL:
Sharma A D, Gupte P D, Sundaram M, Janaki V R, Rege V L, Bilimoria F E, Arora J. Response by the authors. Indian J Dermatol Venereol Leprol [serial online] 2003 [cited 2019 Oct 16];69:430. Available from: http://www.ijdvl.com/text.asp?2003/69/6/430/6639


Sir,
Lincomycin, belonging to the group of lincosamides, has been in use for the past 40 years.[1] The incidence of resistance associated with the use of lincomycin is lower than with some other antibiotics.[2] Earlier in vitro studies have demonstrated the effect of lincomycin against Propionibacterium acnes,[3] the organism implicated in acne.

Recent reports have suggested that P. acnes has developed resistance to a number of commonly used topical anti-acne agents.[4] The major aim of development of a topical formulation of lincomycin, the first of its kind, was to have a newer topical antibiotic to which the organism had not been earlier exposed. Lincomycin gel was therefore developed as a potent topical anti-acne agent. As it is an original formulation developed by Wallace Pharmaceuticals, acute and chronic toxicity studies were performed,[5] followed by a multicentric clinical study[6] to determine its efficacy. These have proved that the formulation was effective and well tolerated. As a topical formulation is available only in India recently, this has not been mentioned in textbooks.

As regards its safety profile, the study compared lincomycin gel with the base used (placebo) and demonstrated that adverse effects with the active drug were no more than with the placebo. Further comparative studies with other available anti-acne agents should be useful in determining the comparative efficacy and tolerability of lincomycin gel. 

      References Top

1.Herrel WE. Lincomycin. Chicago: Modern Scientific Publications; 1969.  Back to cited text no. 1    
2.Dollery C. Therapeutic drugs. 1st ed. Edinburgh: Churchill Livingstone; 1991.  Back to cited text no. 2    
3.Unkles SE, Gemmell CG. Effect of clindamycin, erythromycin, lincomycin and tetracycline on growth and extracellular lipase production by propionibacterium in vitro. Antimicrob Agents Chemother 1982;21:39-43.  Back to cited text no. 3  [PUBMED]  
4.Eady EA, Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM. Antibiotic resistant propionobacterium in acne: Need for policies to modify antibiotic usage. BMJ 1993;306:555-6.  Back to cited text no. 4  [PUBMED]  
5.Data on file, Wallace Pharmaceuticals, Mumbai, India.  Back to cited text no. 5    
6.Sharma AD, Gupte PD, Sundaram M, Janaki VR, Rege VL, et al. Topical lincomycin gel in acne vulgaris: A multicentric placebo controlled study. Indian J Dermatol Venereol Leprol 2003;69:271-3.  Back to cited text no. 6    

 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow